Genentech
It remains to be seen how precision oncology drug and genetic test developers will improve representation of racial and ethnic minorities based on the agency's guidelines.
Roche Immunotherapy Combo Misses Progression-Free Survival Endpoint in First-Line NSCLC Trial
The SKYSCRAPER-01 trial of tiragolumab plus Tecentriq will continue to assess how the combination impacts PD-L1-positive advanced NSCLC patients' overall survival.
Drugmakers Come Together Hoping to Formalize MRD as Surrogate Endpoint in AML Trials
MPAACT members will share trial data, aiming to standardize measurable residual disease as a surrogate endpoint for overall survival and speed up drug development. Â
UK's NICE Recommends Against Merck's Keytruda, Chemo Combo for Advanced PD-L1-Positive TNBC
In a draft guidance, the committee raised concerns about the lack of evidence comparing Keytruda-chemo to Tecentriq-chemo, which is already available for patients in England.
NICE Recommends Seagen's Tukysa for Advanced HER2-Positive Breast Cancer in England
The body has changed its mind based on new data and a discounted price and is now recommending Tukysa plus Herceptin and capecitabine in this setting.